WVE - Wave Life Sciences Ltd.
IEX Last Trade
5.48
0 0%
Share volume: 587,839
Last Updated: Mon 23 Dec 2024 03:34:41 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.51%
PREVIOUS CLOSE
CHG
CHG%
$5.48
8.06
0.60%
Fundamental analysis
32%
Profitability
35%
Dept financing
50%
Liquidity
75%
Performance
15%
Performance
5 Days
3.21%
1 Month
-9.27%
3 Months
153.00%
6 Months
159.31%
1 Year
176.84%
2 Year
107.53%
Key data
Stock price
$5.48
DAY RANGE
$13.50 - $13.72
52 WEEK RANGE
$3.73 - $16.74
52 WEEK CHANGE
$176.84
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Paul B. Bolno
Region: US
Website: wavelifesciences.com
Employees: 240
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: wavelifesciences.com
Employees: 240
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. It focuses on developing GalNAc-conjugated AIMers to treat hepatic indications.
Recent news